BIOAUXILIUM-RESEARCH-INC
Bioauxilium Research Inc. , a Canadian biotech specialized in the development and manufacturing of world-class time-resolved Förster resonance energy transfer (TR‑FRET) assay kits, announced today the launch of its proprietary no-wash THUNDER™ TR‑FRET cellular platform with the introduction of 68 new cell signaling assay kits. These top-quality, fully validated yet affordable cell-based kinase kits were designed to enable the simple, rapid and sensitive semi-quantitative detection of specific intracellular phosphorylated and/or total proteins in cell lysates.
The ready-to-use THUNDER™ Cell Signaling Assay Kits are based on the higher specificity sandwich immunoassay format. However, in contrast to both conventional and improved ELISAs, they use a no-wash protocol with only one reagent addition and incubation step. This streamlined protocol dramatically decreases hands-on time and assay variability and is easily amenable to automation for high-throughput screening (HTS). The assays can be run in the same low volume using either half-area 96-well or low-volume 384-well plates.
The THUNDER™ assay kits combine rigorously validated antibodies, the best compatible FRET fluorophores and stringent manufacturing standards to ensure specificity, enhanced TR‑FRET assay performance and lot-to-lot consistency. All kits are subjected to a rigorous validation process using lysates from cells treated with pathway-specific activators and inhibitors, to further confirm target specificity and demonstrate performance under real assay conditions. Validation data are included in the accompanying datasheets, the most comprehensive on the market. All kits are available in several kit sizes suitable for both lab-scale experiments and high-throughput screens.
“THUNDER™ is an affordable cell-based assay platform that provides easy access to the powerful TR‑FRET technology for all researchers looking to quantify low amounts of endogenous proteins in cells,” said Jaime Padros, Ph.D., President, Bioauxilium. “We believe THUNDER™ provides for the first time a real, cost-effective alternative to ELISAs and other proprietary TR‑FRET as well as bead-based assay technologies.”
THUNDER™ kits are available worldwide and can be purchased directly through the Bioauxilium website or through one of Bioauxilium’s authorized distributors.
The THUNDER™ TR‑FRET technology is also available on request to Bioauxilium’s customers for custom antibody labelling and assay development services.
For more information on Bioauxilium and THUNDER™, visit www.bioauxilium.com .
About Bioauxilium Research Inc.
Bioauxilium is a private Canadian biotechnology company founded by expert industry scientists. It focuses on the design, development and manufacturing of top-quality, fully-validated assay kits that simplify laboratory workflow and accelerate biomedical research. Since its inception in 2013, Bioauxilium has licensed hundreds of TR‑FRET assay kits enabling the quantification of cellular proteins and biomarkers. Bioauxilium’s kits are based on its proprietary THUNDER™ TR-FRET technology. They are offered at an outstanding value and are supported by expert technical support. Bioauxilium also provides on a contract basis customized services in assay development using diverse technologies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200219005603/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom